From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
LDX
30 mg/d (n=44)
50 mg/d (n=112)
70 mg/d (n=171)
All Doses (n=327)
Clinical response, n (%)
42 (95.5)
107 (95.5)
164 (95.9)
313 (95.7a)
Symptomatic remission, n (%)
38 (86.4)
95 (84.8)
145 (84.8)
278 (85.0b)